Market Overview

NHS Hospitals Turn to Deep Learning and Advanced Algorithms to Fight Heart Disease

Share:
  • The HeartFlow Analysis is now available in 13 hospitals in England to
    help physicians diagnose Coronary Heart Disease, one of the leading
    causes of death in the UK
  • The National Institute for Health and Care Excellence (NICE) estimates
    that the HeartFlow Analysis can save the NHS a potential £9.1 million
    per year

New technology using deep learning and advanced algorithms to evaluate
blood flow to the heart is now being used in English hospitals to fight
against coronary heart disease.

Coronary heart disease (CHD) is one of the leading causes of death in
the UK. It is responsible for more than 66,000 deaths each year and it
is estimated that 2.3 million people in the UK are currently living with
the diseasei. CHD develops when the arteries leading to the
heart narrow or become blocked, which can reduce blood flow, and cause
chest pain and heart attacksii.

The HeartFlow® FFRct Analysis is being supported by NHS
England as part of the Innovation and Technology Payment (ITP) programme
to help physicians better diagnose coronary heart disease. It provides
the highest diagnostic performance compared to other commonly available
testsiii and is able to help physicians identify coronary
disease often missed by other tests, while reducing the need for
unnecessary tests, such as an invasive diagnostic angiogramiv. The
National Institute for Health and Care Excellence (NICE) estimates
HeartFlow can save the NHS approximately £9.1 million per yearv.

Under the ITP, the HeartFlow Analysis is currently available in 13
hospitals across the country with a view of being rolled out in more
than 35 hospitals by the year's end.

Currently, it takes most hospitals several weeks to diagnose and develop
a treatment plan for coronary heart disease. HeartFlow may be able to
help shorten this timeline.

Using deep learning and state-of-the-art data processing following a
coronary computed tomography (CT) scan, the HeartFlow Analysis creates a
detailed digital 3D model of the patient's arteries. It then applies
advanced algorithms to solve millions of complex equations to assess the
impact of any blockages on blood flow to the heart.

People experiencing chest pain should visit their GP or a rapid access
chest pain clinic, where a physician can request a CT scan. If needed, a
HeartFlow Analysis can be applied to CT scan results for patients.

Professor Tony Young, national clinical lead for innovation, NHS
England, said:
 "To allow exciting innovations to flourish and
spread, NHS England has footed the bill for a select group of products,
such as the HeartFlow Analysis which could reduce the need for invasive
tests, so patients can benefit faster.

"From the very beginning the NHS has been at the forefront of driving
innovation. As we look to develop our long-term plan, the NHS will
continue to champion world-leading technology."

Dr. Timothy Fairbairn, MBChB, FRCP, Ph.D., consultant cardiologist,
Liverpool Heart and Chest Hospital, said:
"This technology has
exciting benefits for patients, physicians and the NHS. It helps to
diagnose coronary heart disease more quickly and more effectively whilst
reducing reliance on more invasive procedures. In Liverpool, we have
seen how the clinical introduction of the HeartFlow technology is
helping improve patient management by reducing waiting times and
positively influencing clinical decision making.

"The national support for the HeartFlow technology shows the NHS'
commitment to innovation and implementing new technologies that can help
improve the patient experience while delivering the best possible
outcomes."

In recognition of its innovative technology, HeartFlow was recently
awarded the Advanced Diagnostics, Genomics and Precision Medicine Award
by the West Midlands Academic Health Science Network (WMAHSN). The
awards were established in 2016 to recognise and celebrate the work of
individuals and organisations in developing better healthcare and
increasing wealth for local people.

"We are proud to be working with the NHS to make this state-of-the-art
technology available in England, to help physicians diagnose and treat
one of the leading causes of death in the country," said John H.
Stevens, M.D., president and chief executive officer, HeartFlow.
 "We
will be working hard to ensure HeartFlow can help improve the overall
patient experience, by both helping physicians identify heart disease
which may have otherwise been missed and delivering significant cost
benefits to the NHS."

About HeartFlow, Inc.

HeartFlow, Inc. is a medical technology company transforming the way
heart disease is diagnosed and treated. Our non-invasive HeartFlow
Analysis leverages deep learning to create a personalized 3D model of
the heart. By using this model, clinicians can better evaluate the
impact a blockage has on blood flow and determine the best treatment for
patients. Our technology is reflective of our Silicon Valley roots and
incorporates decades of scientific evidence with the latest advances in
artificial intelligence. The HeartFlow Analysis is commercially
available in the United States, Canada, Europe and Japan. For more
information, visit www.heartflow.com.

i https://www.bhf.org.uk/-/media/.../heart-statistics/bhf-cvd-statistics---uk-factsheet.pdf
ii
https://www.nhs.uk/conditions/coronary-heart-disease/
iii
Driessen, et al. Presented at EuroPCR 2018. Nørgaard et al, Euro
Radiology 2015; 25(8):2282-90
iv Douglas et al. PLATFORM
Trial. Eur Heart J. 2015;36(47):3359-67
v https://www.nice.org.uk/about/what-we-do/into-practice/cost-saving-guidance

View Comments and Join the Discussion!